Exam (elaborations)
MN553 ADVANCED PHARMACOLOGY AND PHARMACOTHERAPEUTICS - Cardiovascular & Hematopoietic Systems .
- Course
- Institution
MN553 ADVANCED PHARMACOLOGY AND PHARMACOTHERAPEUTICS - Cardiovascular & Hematopoietic Systems
[Show more]
Seller
Follow
oassignment
Reviews received
Content preview
MN553 ADVANCED PHARMACOLOGYAND PHARMACOTHERAPEUTICS -
Cardiovascular & Hematopoietic
Systems
After serial BP measurements indicate a persistent 150 to 160 systolic in individuals
without other major deep vein risks - answer Medications are initiated after diet and
exercise. Target values below 140 systolic are not rigidly enforced if adherence to
medications and exercise have proven beneficial, especially in elders with hypotensive
episodes.
Targets of below 140 systolic remain for patients with diabetes mellitus (DM).
Emphasis on lifestyle changes continues after medications are started.
Treatment of Hypertension With Higher Cardiovascular (CV) Risk
Stage I: systolic blood pressure (SBP) 140 to 159/diastolic blood pressure (DBP) 90 to
99 - answer Diuretics: thiazide-type
May consider angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor
blocker (ARB), calcium channel blocker (CCB), or combination
Treatment of Hypertension with Higher Cardiovascular Risk
Stage II: SBP greater than or equal to 160/DBP greater than or equal to 100 - answer
Two-drug combination: thiazide-type and ACEI, ARB, beta blocker (BB), or CCB
Treatment of Hypertension with Higher Cardiovascular Risk
With compelling indications: heart failure (HF), DM, stroke, chronic kidney failure, point
of maximal impact - answer Diuretics, ACEI, ARB, BB, CCB as needed
Treatment: Heart Failure
Stage A - answer ACEIs are drug of choice.
ARBs are considered but more expensive.
Heart Failure
Stage B - answer ACEI in all patients, ARB for those who cannot tolerate an ACEI
BBs in most
Heart Failure
Stage C - answer ACEI and BBs (nonselective) in all patients Diuretics, digoxin
Spironolactone
Heart Failure
Stage D - answer Stage C treatments
Inotropes: dobutamine
Ventricular assist device, transplantation, hospice
ACEIs
, MN553 ADVANCED PHARMACOLOGY
AND PHARMACOTHERAPEUTICS -
Cardiovascular & Hematopoietic
Systems
Pharmacodynamics - answer Inhibition of angiotensin-converting enzyme (ACE)
activity results in decreased production of both angiotensin II (AT II) and aldosterone.
Can lower vascular resistance without decreasing cardiac output (CO) or glomerular
filtration rate (GFR).
Does not produce reflex tachycardia.
ACE:
Strong evidence for CV and cerebrovascular risk reduction, HF, and slowing renal
disease - answer Improves oxygenation to heart muscle, decreases inappropriate
remodeling of heart muscle after myocardial infarction (MI) or with heart failure, reduces
affects of diabetes on the kidneys
ACE: diabetes, hyperlipidemia - answer Improves insulin sensitivity, does not affect
glucose metabolism or raise serum lipid levels
ACE - answer Benazopril 5 mg if on diuretic; 10 mg if not on diuretic, 80 mg/day
Captopril 25 mg 2 to 3 x day 450 mg/day
Enalapril 2.5 mg twice daily if on diuretic; 5 mg twice daily if not on diuretic 40 mg/day
Fosinopril 10 mg daily 80 mg/day Lisinopril 10 mg daily 80 mg/day
Moexipril 7.5 mg prior to meal once/day 60 mg/day
ACEIs Who to use with, Who not to use with - answer Use with
Young Caucasian patients
Patients with angina: prevents formation of AT II and decreases pulmonary vascular
resistance by decreasing retention of sodium and water and reducing extracellular fluid
and preload Diabetic patients: prevents or slows nephropathy HF patients
Not as effective for African-American patients When combined with a diuretic, race no
longer an issue
However, African Americans and Asians have three to four times greater risk of
developing angioedema.
ACEIs Adverse Reactions - answer Adverse drug reactions (ADRs): dry cough
(bradykininmediated), hypotension, loss of taste, angioedema, blood dyscrasias,
teratogenicity, hyperkalemia, acute renal failure, cholestatic jaundice, pancreatitis, rash
Angiotensin II Receptor Blockers - answer Prevent binding of AT II to receptors in
kidney, brain, heart, and arterial walls
Inhibit the renin-angiotensin-aldosterone system (RAAS) and cause fall in peripheral
resistance Evidence supports use in kidney disease until late stage and heart failure,
but not renal protective like ACEI
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller oassignment. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $16.49. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
75323 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now